FINWIRES · TerminalLIVE
FINWIRES

$KRYS

10 stories mentioning KRYSUpdated 15d ago

Every FINWIRES story that references KRYS, newest first.

What are analysts saying about KRYS?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on KRYS?

Insider Trading

Krystal Biotech Insider Sold Shares Worth $8,983,084, According to a Recent SEC Filing

Krish S Krishnan, 10% Owner, Director, President and Chief Executive Officer, on September 04, 2026, sold 25,000 shares in Krystal Biotech (KRYS) for $8,983,084. Following the Form 4 filing with the SEC, Krishnan has control over a total of 1,565,253 common shares of the company, with 1,347,543 shares held directly and 217,710 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1711279/000129870926000011/xslF345X05/wk-form4_1788563646.xml

$KRYS
Insider Trading

Krystal Biotech Insider Sold Shares Worth $8,982,986, According to a Recent SEC Filing

Suma Krishnan, 10% Owner, Director, President, Research and Development, on September 04, 2026, sold 25,000 shares in Krystal Biotech (KRYS) for $8,982,986. Following the Form 4 filing with the SEC, Krishnan has control over a total of 1,493,155 common shares of the company, with 1,302,145 shares held directly and 191,010 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1711279/000129871126000009/xslF345X05/wk-form4_1788563746.xml

$KRYS
Insider Trading

Krystal Biotech Insider Sold Shares Worth $8,227,953, According to a Recent SEC Filing

Dino A Rossi, Director, on August 14, 2026, sold 25,000 shares in Krystal Biotech (KRYS) for $8,227,953. Following the Form 4 filing with the SEC, Rossi has control over a total of 50,000 common shares of the company, with 50,000 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1711279/000120905926000006/xslF345X05/wk-form4_1786746156.xml

$KRYS
Wire

Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says

Krystal Biotech (KRYS) has further room for gains driven by Vyjuvek, its treatment for the rare blistering condition dystrophic epidermolysis bullosa, alongside international launches and growth across its gene therapy pipeline, RBC Capital said Friday in a report.Krystal's neurotrophic keratitis program could be its next major catalyst, with pivotal data expected in early 2027, RBC said. Shares may rise 30% if results match the current standard of care, while a weak outcome might prompt a 15% decline, the report said.RBC forecasts peak NK sales of $2.1 billion in 2030, citing the established market and potential for the therapy to become a best-in-class treatment, though the outlook remains "cautiously optimistic" given limited clinical data.Vyjuvek holds more than 60% of the US market, while international launches are expected to drive the next phase of growth, the report said. RBC projects Vyjuvek peak sales of $1 billion by 2033 and pointed to H2 readouts in ocular DEB, cystic fibrosis and Hailey-Hailey disease, a skin disorder, as potential catalysts.RBC initiated coverage of Krystal with an outperform rating on the stock and a $400 price target.Price: $326.38, Change: $-1.96, Percent Change: -0.60%

$KRYS
Research

RBC Initiates Krystal Biotech at Outperform, With $400 Price Target

Krystal Biotech (KRYS) has an average rating of buy and mean price target of $385, according to analysts polled by FactSet.

$KRYS
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index falling 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1%.The iShares Biotechnology ETF (IBB) shed 0.2%.In corporate news, Integer (ITGR) agreed to be acquired and taken private by investment firm KKR (KKR) in an all-cash deal with an enterprise value of about $5.7 billion. Integer shares rose 2.6%.AstraZeneca (AZN) is in talks with Bristol Myers Squibb (BMY) about a potential combination that would create a company valued at almost $400 billion, the Financial Times reported Sunday. AstraZeneca shares slumped 6.8%, and Bristol Myers rose 0.4%.Lantheus Holdings (LNTH) agreed to be acquired and taken private by Curium for up to $8 billion. Lantheus shares rose 1.7%.Krystal Biotech (KRYS) shares dropped 8.4% after its Q2 product revenue fell short of analysts' estimates.

$AZN$BMY$ITGR$KRYS$LNTH
Sectors

Sector Update: Healthcare

Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index falling 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1%.The iShares Biotechnology ETF (IBB) shed 0.2%.In corporate news, Krystal Biotech (KRYS) shares dropped 8.3% after its Q2 product revenue fell short of analysts' estimates.

$KRYS
Wire

Update: Krystal Biotech Shares Fall After Q2 Product Revenue Miss

(Updates with the latest stock movement in the first paragraph and headline.)Krystal Biotech (KRYS) shares were down 8.2% in Monday trading after the company's Q2 product revenue fell short of analysts' estimate.The company reported Q2 net income Monday of $1.79 per diluted share, compared with $1.29 a year earlier.Three analysts surveyed by FactSet expected $1.62.Net product revenue for the quarter ended June 30 was $119.2 million, compared with $96 million a year earlier.Analysts expected $120.9 million.Price: $313.00, Change: $-28.12, Percent Change: -8.24%

$KRYS
Insider Trading

Krystal Biotech Insider Sold Shares Worth $7,702,984, According to a Recent SEC Filing

Krish S Krishnan, 10% Owner, Director, President and Chief Executive Officer, on June 04, 2026, sold 25,000 shares in Krystal Biotech (KRYS) for $7,702,984. Following the Form 4 filing with the SEC, Krishnan has control over a total of 1,590,253 common shares of the company, with 1,450,253 shares held directly and 140,000 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1711279/000129870926000009/xslF345X05/wk-form4_1780699113.xml

$KRYS
Wire

Krystal Biotech's Medicine to Treat Wounds in Dystrophic Epidermolysis Bullosa Gets Approval in UK

Krystal Biotech's (KRYS) beremagene geperpavec to treat wounds in patients with dystrophic epidermolysis bullosa has received approval from the UK's Medicines and Healthcare products Regulatory Agency for use from birth onward, the agency said in a Friday statement.The medication, which is available in the form of gel, demonstrated 67% complete healing rate in a study of 31 patients at six months, according to the statement.Dystrophic epidermolysis bullosa is a rare genetic condition characterized by fragile skin and recurrent wounds.Price: $308.93, Change: $-7.37, Percent Change: -2.33%

$KRYS

Track with the FINWIRES app suite

FolioX
FolioX
Track KRYS in your portfolio
WheelAI
WheelAI
Analyze KRYS options with the wheel strategy
StockInsider
StockInsider
See market sentiment on KRYS